文献速递白血病造血干细胞移植与细胞治疗

儿童ALL预处理:全身照射对比化疗的随机III期非劣效研究

Total Body Irradiation or Chemotherapy Conditioning in Childhood ALL: A Multinational, Randomized, Noninferiority Phase III Study.
PubMed 文献 · J Clin Oncol · 2020-12-17

FORUM研究为国际多中心随机III期非劣效试验,纳入417例拟行异基因HSCT的儿童ALL患者,比较分次12 Gy TBI联合依托泊苷与氟达拉滨、噻替派联合白消安或曲奥舒凡的化疗预处理。因化疗组显著劣于TBI组触发终止规则,TBI组2年OS显著更高(0.91 vs 0.75),复发累积发生率更低,治疗相关死亡率亦更低。结论推荐TBI联合依托泊苷用于>4岁高危ALL的异基因HSCT预处理。

要点

  • TBI联合依托泊苷组2年OS为0.91,显著高于化疗预处理组的0.75。
  • TBI组2年复发累积发生率为0.12,显著低于化疗组的0.33。
  • TBI组治疗相关死亡率为0.02,低于化疗组的0.09。

核心结论

  • TBI联合依托泊苷较化疗预处理显著提高2年OS并降低复发风险。
  • 推荐TBI联合依托泊苷用于>4岁高危ALL患者的异基因HSCT预处理。

研究设计与样本

  • FORUM为随机、对照、开放标签、国际多中心III期非劣效研究。
  • 纳入诊断时≤18岁、HSCT时4-21岁、HSCT前完全缓解且有HLA相合同胞或无关供者的患者。
  • 随机分配至分次12 Gy TBI联合依托泊苷组或氟达拉滨、噻替派联合白消安或曲奥舒凡组。
  • 非劣效界值为8%,计划5年随机1000例,最少随访2年,单侧α为5%,把握度80%。
  • 实际筛查543例,随机417例,TBI组212例,化疗组201例;因无效性终止规则于2019年3月31日停止。

主要发现

  • 中位随访2.1年,意向治疗人群中TBI组2年OS为0.91(95%CI 0.86-0.95),化疗组为0.75(95%CI 0.67-0.81),P<.0001。
  • TBI组2年复发累积发生率为0.12(95%CI 0.08-0.17),化疗组为0.33(95%CI 0.25-0.40),P<.0001。
  • TBI组2年治疗相关死亡率为0.02(95%CI <0.01-0.05),化疗组为0.09(95%CI 0.05-0.14),P=.0269。

关键数值与推荐

  • 非劣效界值为8%。
  • TBI方案为分次12 Gy联合依托泊苷。
  • 化疗方案为氟达拉滨、噻替派联合白消安或曲奥舒凡。

临床怎么用

  • 对>4岁高危ALL行异基因HSCT时,优先选择TBI联合依托泊苷预处理。
  • 化疗预处理组复发风险和治疗相关死亡率均较高,不宜替代TBI。

局限性

  • 研究因无效性终止规则提前停止,实际随机417例而非计划的1000例。
  • 中位随访仅2.1年,长期疗效与远期副作用尚未报告。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Total body irradiation (TBI) before allogeneic hematopoietic stem cell transplantation (HSCT) in pediatric patients with acute lymphoblastic leukemia (ALL) is efficacious, but long-term side effects are concerning. We investigated whether preparative combination chemotherapy could replace TBI in such patients. PATIENTS AND METHODS: FORUM is a randomized, controlled, open-label, international, multicenter, phase III, noninferiority study. Patients ≤ 18 years at diagnosis, 4-21 years at HSCT, in complete remission pre-HSCT, and with an HLA-compatible related or unrelated donor were randomly assigned to myeloablative conditioning with fractionated 12 Gy TBI and etoposide versus fludarabine, thiotepa, and either busulfan or treosulfan. The noninferiority margin was 8%. With 1,000 patients randomly assigned in 5 years, 2-year minimum follow-up, and one-sided alpha of 5%, 80% power was calculated. A futility stopping rule would halt random assignment if chemoconditioning was significantly inferior to TBI (EudraCT: 2012-003032-22; ClinicalTrials.gov: NCT01949129). RESULTS: Between April 2013 and December 2018, 543 patients were screened, 417 were randomly assigned, 212 received TBI, and 201 received chemoconditioning. The stopping rule was applied on March 31, 2019. The median follow-up was 2.1 years. In the intention-to-treat population, 2-year overall survival (OS) was significantly higher following TBI (0.91; 95% CI, 0.86 to 0.95; P < .0001) versus chemoconditioning (0.75; 95% CI, 0.67 to 0.81). Two-year cumulative incidence of relapse and treatment-related mortality were 0.12 (95% CI, 0.08 to 0.17; P < .0001) and 0.02 (95% CI, < 0.01 to 0.05; P = .0269) following TBI and 0.33 (95% CI, 0.25 to 0.40) and 0.09 (95% CI, 0.05 to 0.14) following chemoconditioning, respectively. CONCLUSION: Improved OS and lower relapse risk were observed following TBI plus etoposide compared with chemoconditioning. We therefore recommend TBI plus etoposide for patients > 4 years old with high-risk ALL undergoing allogeneic HSCT.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Peters C, Dalle JH, Locatelli F, et al. Total Body Irradiation or Chemotherapy Conditioning in Childhood ALL: A Multinational, Randomized, Noninferiority Phase III Study. J Clin Oncol. 2020. PMID: 33332189. doi:10.1200/JCO.20.02529

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。